Publications by authors named "Lewis Kaninda Badibabi"
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Lancet Infect Dis
April 2023
Background: Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also requires systematic admission to hospital, which is problematic in areas with few health-care resources. We aim to assess the safety and efficacy of acoziborole in adult and adolescent patients with gambiense HAT.
View Article and Find Full Text PDFSafety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial.
Lancet Glob Health
November 2022
Background: Fexinidazole has been reported as an effective oral monotherapy against non-severe gambiense human African trypanosomiasis in a recent trial in adults. We aimed to assess the safety and efficacy of fexinidazole in children across all disease stages of gambiense human African trypanosomiasis.
Methods: We did a multicentre, single-arm, open-label, phase 2-3 trial at eight district hospitals in the Democratic Republic of the Congo.
Article Synopsis
- Late-stage human African trypanosomiasis (g-HAT), caused by Trypanosoma brucei gambiense, has limited treatment options, typically requiring hospital-administered combination therapy, which is impractical for patients in remote areas.
- This study evaluated the safety and efficacy of an oral medication, fexinidazole, compared to the standard nifurtimox and eflornithine combination therapy in patients with late-stage g-HAT in the Democratic Republic of the Congo and Central African Republic.
- The trial was a randomized, open-label study with a primary endpoint measuring treatment success at 18 months, involving monitoring for both efficacy and safety of the medications administered.